Outcome of antithrombotic therapy in cancer patients with catheter-related thrombosis: a systematic review

Qinan Yin; Xingyue Zheng; Lizhu Han; Xuefei Huang; Yueyuan Wang; Yujie Song; Yuan Zhang; Yuan Bian

doi:10.3389/fcvm.2023.1290822

Outcome of antithrombotic therapy in cancer patients with catheter-related thrombosis: a systematic review

Front Cardiovasc Med. 2023 Dec 12:10:1290822. doi: 10.3389/fcvm.2023.1290822. eCollection 2023.

Authors

Qinan Yin^#^{1

2}, Xingyue Zheng^#², Lizhu Han^{1

2}, Xuefei Huang^{1

2}, Yueyuan Wang^{1

2}, Yujie Song^{1

2}, Yuan Zhang^{1

2}, Yuan Bian^{1

2}

Affiliations

¹ Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
² Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

^# Contributed equally.

Abstract

Introduction: The guidelines' recommendations for anticoagulation in cancer patients with catheter-related thrombosis are unclear. The aim of this systematic review was to assess anticoagulation management in cancer patients with catheter-related thrombosis (CRT) based on previously published studies.

Methods: As of June 10, 2023,we searched databases including PubMed, Embase, and Cochrane and included 11 observational studies that met the criteria. We evaluated 770 adults with active cancer and objectively confirmed patients with CRT who were using drugs including warfarin, LMWH, and new oral anticoagulants as antithrombotic therapy.

Results: We extracted outcome data, including thrombosis recurrence, catheter dysfunction, major bleeding, and death, and performed a meta-analysis.

Discussion: In this study we found that the risk of VTE recurrence was higher with rivaroxaban, the risk of bleeding and death appeared to be greater with warfarin, and although the risk of catheter dysfunction due to LMWH is a concern, it is still a more reasonable option for cancer patients with catheter-related thrombosis.

Systematic review registration: http://www.clinicaltrials.gov, identifier (CRD42022367979).

Keywords: DOACs; LMWH; VKAs; anticoagulation; cancer patients; catheter-related thrombosis; systematic review.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.